Startup profile · funding coverage
Alpha-9 Oncology funding, valuation and investors
Clinical-stage radiopharmaceutical company developing targeted cancer therapies.
Keep track of Alpha-9 Oncology
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series C
$175M · 2024
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$175M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth
Investors in latest funding
Other: Andreessen Horowitz
Overview
Alpha-9 Oncology develops targeted radiopharmaceutical therapies for cancer — a clinical-stage biotech with a systematic engine for designing ligands across oncology targets.
Why Alpha-9 Oncology is interesting
Systematic radiopharma design engine across validated and novel oncology targets — oversubscribed Series C at scale.
Product & use cases
Alpha-9 Oncology develops targeted radiopharmaceutical therapies for cancer — a clinical-stage biotech with a systematic engine for designing ligands across oncology targets.
- Healthcare provider and health-system operations
Key facts
- Series C (2024): $175M led by Lightspeed and Ascenta with a16z Bio + Health, General Catalyst (company press)
- Clinical-stage radiopharmaceutical platform targeting multiple oncology indications via systematic ligand design
- Co-investors not in VCT directory: Ascenta Capital
Funding history (newest first)
Series C
2024 $175MSource: Series C (2024): $175M led by Lightspeed and Ascenta with a16z Bio + Health, General Catalyst (company press)
Investors in our directory
Funds linked from Alpha-9 Oncology's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Systematic radiopharma design engine across validated and novel oncology targets — oversubscribed Series C at scale.
Alpha-9 Oncology competes in biotech-life-sciences, healthtech. Incumbents have distribution; startup edge depends on product depth and buyer references. See competitors for specific tradeoffs — no invented market share claims.
-
Veeva incumbent
Life sciences cloud incumbent.
-
Dotmatics adjacent
R&D informatics.
-
Epic Systems incumbent
Dominant EHR incumbent.
-
Oracle Health incumbent
Enterprise EHR competitor.
Notable stories
- Series C (2024): $175M led by Lightspeed and Ascenta with a16z Bio + Health, General Catalyst (company press)
- Clinical-stage radiopharmaceutical platform targeting multiple oncology indications via systematic ligand design
Industries
Related funding articles
Venture Capital Tracker pieces that cover Alpha-9 Oncology's financing or category context.
FAQs about Alpha-9 Oncology
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.